Sorry, you need to enable JavaScript to visit this website.

MYLOTARG™ (gemtuzumab ozogamicin) Boxed Warning

WARNING: HEPATOTOXICITY

Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of MYLOTARG as a single agent, and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of VOD after treatment with MYLOTARG. (5.1 and 6.1)

What's New

No Current Announcements.

Search

Please enter your search term(s) for MYLOTARG™